2.225
price down icon0.48%   -0.025
 
loading
C 4 Therapeutics Inc stock is traded at $2.225, with a volume of 95,597. It is down -0.48% in the last 24 hours and down -15.82% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.25
Open:
$2.25
24h Volume:
95,597
Relative Volume:
0.05
Market Cap:
$159.42M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.8333
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
-1.79%
1M Performance:
-15.82%
6M Performance:
+80.58%
1Y Performance:
-58.99%
1-Day Range:
Value
$2.22
$2.27
1-Week Range:
Value
$2.16
$2.50
52-Week Range:
Value
$1.085
$7.14

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name
Name
C 4 Therapeutics Inc
Name
Phone
(617) 231-0700
Name
Address
490 ARSENAL WAY, WATERTOWN
Name
Employee
110
Name
Twitter
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CCCC
C 4 Therapeutics Inc
2.24 160.13M 20.76M -132.49M -108.55M -2.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
406.19 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
459.29 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.50 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
795.94 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
326.40 35.16B 4.56B -176.77M 225.30M -1.7177

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-17-25 Initiated Barclays Overweight
Sep-15-25 Upgrade Stephens Equal-Weight → Overweight
Sep-04-25 Initiated Guggenheim Buy
Dec-19-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-18-24 Initiated Stephens Equal-Weight
Jan-29-24 Upgrade JP Morgan Underweight → Neutral
Dec-13-23 Upgrade Stifel Hold → Buy
Feb-24-23 Upgrade Credit Suisse Underperform → Neutral
Feb-24-23 Downgrade JP Morgan Neutral → Underweight
Nov-04-22 Downgrade JP Morgan Overweight → Neutral
Oct-11-22 Initiated Morgan Stanley Underweight
Apr-28-22 Initiated Credit Suisse Underperform
Apr-11-22 Downgrade BofA Securities Buy → Neutral
Mar-10-22 Initiated JP Morgan Overweight
Feb-11-22 Resumed BMO Capital Markets Outperform
Feb-10-22 Initiated Wells Fargo Equal Weight
Nov-23-21 Initiated BofA Securities Buy
Oct-14-21 Initiated SVB Leerink Mkt Perform
Sep-30-21 Initiated Stifel Hold
Jun-04-21 Initiated H.C. Wainwright Buy
Mar-31-21 Initiated BMO Capital Markets Outperform
Oct-28-20 Initiated UBS Buy
Oct-27-20 Initiated BMO Capital Markets Outperform
Oct-27-20 Initiated Jefferies Buy
View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

pulisher
Oct 12, 2025

How C4 Therapeutics Inc. stock reacts to oil prices2025 Volatility Report & Risk Managed Investment Signals - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 10, 2025
pulisher
Oct 10, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 10, 2025
pulisher
Oct 10, 2025

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 10, 2025
pulisher
Oct 10, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 10, 2025
pulisher
Oct 10, 2025

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 10, 2025
pulisher
Oct 10, 2025

C4 Therapeutics Reports Promising Phase 1 Trial Results - MSN

Oct 10, 2025
pulisher
Oct 09, 2025

C4 Therapeutics (NASDAQ:CCCC) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

C4 Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Low Risk Trading Ideas - earlytimes.in

Oct 09, 2025
pulisher
Oct 07, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 07, 2025
pulisher
Oct 06, 2025

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 06, 2025
pulisher
Oct 06, 2025

Is C4 Therapeutics Inc. trending in predictive chart modelsWeekly Risk Report & High Yield Equity Trading Tips - newser.com

Oct 06, 2025
pulisher
Oct 04, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 04, 2025
pulisher
Oct 03, 2025

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 03, 2025
pulisher
Oct 03, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire

Oct 03, 2025
pulisher
Oct 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Oct 03, 2025
pulisher
Oct 03, 2025

Will C4 Therapeutics Inc. bounce back from current supportBreakout Watch & Low Drawdown Momentum Ideas - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 03, 2025
pulisher
Oct 02, 2025

What analysts say about C4 Therapeutics Inc stockCup and Handle Formations & Capital Allocation Recommendations - earlytimes.in

Oct 02, 2025
pulisher
Oct 02, 2025

Is Onix Solar Energy Limited Undervalued or Overvalued Fair Value ExplainedHigh Frequency Trading Trends & Small Entry Investment Ideas - earlytimes.in

Oct 02, 2025
pulisher
Oct 02, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2025
pulisher
Oct 02, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 02, 2025
pulisher
Oct 02, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 02, 2025
pulisher
Oct 02, 2025

C4 Therapeutics Announces Clinical Trial Collaboration and - GlobeNewswire

Oct 02, 2025
pulisher
Oct 02, 2025

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2025
pulisher
Oct 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm

Oct 01, 2025
pulisher
Oct 01, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 01, 2025
pulisher
Oct 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 01, 2025
pulisher
Oct 01, 2025

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 01, 2025
pulisher
Oct 01, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WV News

Oct 01, 2025
pulisher
Oct 01, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 01, 2025
pulisher
Oct 01, 2025

Biotech Firm Protara Therapeutics Issues $4.41 Stock Options and RSUs in Key Employee Grant - Stock Titan

Oct 01, 2025
pulisher
Oct 01, 2025

C4 Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma - MarketScreener

Oct 01, 2025
pulisher
Oct 01, 2025

C4 Therapeutics Partners with Pfizer for Phase 1b Clinical Trial of Cemsidomide in Combination with Elranatamab for Multiple Myeloma Treatment - Quiver Quantitative

Oct 01, 2025
pulisher
Oct 01, 2025

Breakthrough Multiple Myeloma Treatment: C4 Therapeutics and Pfizer Join Forces for Novel Drug Combination Trial - Stock Titan

Oct 01, 2025
pulisher
Sep 30, 2025

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 30, 2025
pulisher
Sep 29, 2025

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Sep 29, 2025
pulisher
Sep 29, 2025

Analyzing C4 Therapeutics Inc. with risk reward ratio chartsRate Cut & High Conviction Buy Zone Picks - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Has C4 Therapeutics Inc. formed a bullish divergenceJuly 2025 Earnings & Precise Buy Zone Identification - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Risk adjusted return profile for C4 Therapeutics Inc. analyzedJuly 2025 Technicals & Real-Time Volume Triggers - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Will C4 Therapeutics Inc. stock maintain momentum in 2025July 2025 Earnings & Risk Adjusted Buy and Sell Alerts - newser.com

Sep 28, 2025
pulisher
Sep 27, 2025

How to monitor C4 Therapeutics Inc. with trend dashboardsWeekly Loss Report & Reliable Price Breakout Alerts - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Will C4 Therapeutics Inc. benefit from macro trendsWeekly Stock Recap & High Accuracy Buy Signal Tips - newser.com

Sep 27, 2025

C 4 Therapeutics Inc Stock (CCCC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

C 4 Therapeutics Inc Stock (CCCC) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Boyle Scott N
Chief Business Officer
Feb 14 '25
Sale
3.15
490
1,544
110,842
$21.84
price up icon 2.36%
$83.23
price down icon 0.83%
$32.01
price up icon 0.52%
$101.95
price down icon 0.60%
$163.94
price up icon 0.83%
biotechnology ONC
$326.40
price up icon 1.37%
Cap:     |  Volume (24h):